Anterior gradient-2 plays a critical role in breast cancer cell growth and survival by modulating cyclin D1, estrogen receptor-α and survivin
Open Access
- 4 June 2010
- journal article
- Published by Springer Science and Business Media LLC in Breast Cancer Research
- Vol. 12 (3), R32
- https://doi.org/10.1186/bcr2586
Abstract
Anterior-gradient 2 (AGR2) is an estrogen-responsive secreted protein. Its upregulation has been well documented in a number of cancers, particularly breast cancer, for which mixed data exist on the prognostic implications of AGR2 expression. Although emerging evidence indicates that AGR2 is associated with poor prognosis, its function and impact on cancer-relevant pathways have not been elucidated in breast cancer.Keywords
This publication has 45 references indexed in Scilit:
- Human Homologue of Cement Gland Protein, a Novel Metastasis Inducer Associated with Breast CarcinomasCancer Research, 2005
- Mechanisms of tamoxifen resistanceEndocrine-Related Cancer, 2004
- Estrogen Receptor Breast Cancer Phenotypes in the Surveillance, Epidemiology, and End Results DatabaseBreast Cancer Research and Treatment, 2002
- Cycling to Cancer with Cyclin D1Cancer Biology & Therapy, 2002
- Specific protection against breast cancers by cyclin D1 ablationNature, 2001
- hAG-2, the Human Homologue of theXenopus laevisCement Gland Gene XAG-2, Is Coexpressed with Estrogen Receptor in Breast Cancer Cell LinesBiochemical and Biophysical Research Communications, 1998
- 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells.1996
- Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining.1994
- D-type cyclin-dependent kinase activity in mammalian cells.Molecular and Cellular Biology, 1994
- Mechanism of estrogen activation of c-myc oncogene expression.1992